OBI-201 / OBI Pharma - LARVOL DELTA

Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery (AACR 2026) - "Using a guide-effector mechanism, BsAbs pair a rapidly internalizing receptor (e.g., HER2 or c-MET) with a poorly internalizing one (e.g., TROP2 or HER3), leveraging the guide receptor's endocytic capacity to drive co-endocytosis and lysosomal trafficking.HER2 × TROP2 BsADC (OBI-201) illustrates this concept: HER2 facilitates co-internalization of TROP2 (1.7-fold increase compared to the mono-ADC), enhancing lysosomal trafficking and intracellular payload delivery in tumors co-expressing both receptors, overcoming resistance seen with monospecific antibodies and improving cytotoxic efficacy. Similarly, c-MET × HER3 BsAbs exploit c-MET's rapid internalization to drive HER3 uptake (5.5-fold increase compared to the HER3 mono-Ab), inducing receptor clustering, coordinated lysosomal trafficking, and increased intracellular payload delivery, thereby enhancing antitumor activity.These findings show that BsAbs enhance receptor internalization via..."

ADC • Oncology • ERBB3 • HER-2 • MET

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies (ACN Newswire) - "Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ADC enabling technologies(GlycOBI and GlycOBI DUO."

Preclinical • Oncology

Obi‑201: a bispecific trop2 × her2 antibody-drug conjugate to expand therapeutic reach beyond her2-low limitations (SABCS 2025) - "OBI‑201 demonstrated superior antitumor activity compared to Enhertu®, Datroway®, and Trodelvy® in HER2-low colorectal, pancreatic, and NSCLC models, as well as in Enhertu-resistant NSCLC CDX models. OBI-201 is a next-generation bispecific ADC targeting HER2 and TROP2, designed to overcome the limitations of single-target therapies. Its dual-targeting approach, enabled by GlycOBI®, proprietary ADC enabling technologies for precise payload delivery, offers strong potential to overcome HER2-low expression and resistance, addressing significant unmet needs across a broad spectrum of solid tumors."

Breast Cancer • Triple Negative Breast Cancer • TACSTD2